Idexx Laboratories Inc

  • Health Care
  • Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • www.idexx.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $35.74B
  • PE 41
  • Debt $623.90M
  • Cash $308.64M
  • EV $36.06B
  • FCF $792.60M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$866.24M
EBIT$1.11B
ROE54%
ROA33%
FCF$792.60M
Equity$1.62B
Growth Stability100%
PE41.26
PEG2.85
PB22.09
P/FCF45.1
P/S9.3
Price/Cash0.01
Debt/Equity0.39
Debt/FCF0.79
Net Margins23%
Gross Margins61%
Op. Margins29%
Earnings CAGR21%
Sales Growth YoY7%
Sales Growth QoQ-3%
Sales CAGR11%
FCF CAGR18%
Equity CAGR37%
Earnings Stability0.95
Earnings Growth YoY10%
Earnings Growth QoQ15%
Earnings CAGR 5Y15%
Sales CAGR 5Y10%
FCF CAGR 5Y16%
Equity CAGR 5Y52%
Earnings CAGR 3Y7%
Sales CAGR 3Y7%
FCF CAGR 3Y22%
Equity CAGR 3Y62%
Market Cap$35.74B
Revenue$3.84B
Assets$3.35B
Total Debt$623.90M
Cash$308.64M
Shares Outstanding82.04M
EV36.06B
Earnings Score95%
Moat Score98%
Safety Score96%
Final Score96%
Working Capital424.52M
Current Ratio1.42
Gross Profit$2.33B
Shares Growth 3y-1%
Equity Growth QoQ2%
Equity Growth YoY25%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

SEC Filings

Direct access to Idexx Laboratories Inc (IDXX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Idexx Laboratories Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Idexx Laboratories Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 21%
Stability 95%
loading chart...

Idexx Laboratories Inc Discounted Cash Flow

Fully customizable DCF calculator online for Idexx Laboratories Inc .

= $27B
012345678910TV
fcf$793M$932M$1.1B$1.3B$1.5B$1.8B$2.1B$2.5B$2.9B$3.4B$4B$40B
DCF$847M$906M$969M$1B$1.1B$1.2B$1.3B$1.4B$1.4B$1.5B$15B
Value$27B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins12%12%13%13%17%18%21%23%20%23%23%
ROA-21%23%24%32%30%30%38%33%34%33%
ROE--229%-205%-489%-4K%241%92%108%112%57%54%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-4.472.22.032.122.31.771.462.1410.79
Debt over Equity2.98-7.11-5.49-11.27-65.183.931.521.341.390.520.39
Growth Stability---100%100%100%100%100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-8%11%11%12%9%12%19%5%9%10%
Earnings YoY growth-6%16%19%43%13%36%28%-9%24%15%
Equity YoY growth--171%29%-50%-83%-2K%256%9%-12%144%52%
FCF YoY growth--24%102%11%-5%7%78%18%-38%96%16%